Kyntra Bio (NASDAQ:KYNB – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $43.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 452.70% from the stock’s previous close.
Several other equities analysts have also commented on the company. Weiss Ratings upgraded Kyntra Bio from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, August 14th. Rodman & Renshaw assumed coverage on Kyntra Bio in a research note on Tuesday, June 9th. They issued a “buy” rating and a $30.00 target price for the company. Finally, Oppenheimer started coverage on shares of Kyntra Bio in a research report on Monday, July 6th. They set an “outperform” rating and a $35.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kyntra Bio presently has an average rating of “Hold” and an average price target of $36.00.
View Our Latest Stock Report on Kyntra Bio
Kyntra Bio Stock Down 3.0%
Institutional Trading of Kyntra Bio
An institutional investor recently bought a new stake in Kyntra Bio stock. Renaissance Technologies LLC bought a new position in Kyntra Bio Inc (NASDAQ:KYNB – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 27,481 shares of the company’s stock, valued at approximately $186,000. Renaissance Technologies LLC owned about 0.68% of Kyntra Bio as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 72.71% of the company’s stock.
Kyntra Bio Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Stories
- Five stocks we like better than Kyntra Bio
- 3 Space Stocks: Ready for Liftoff or Burning Up on Reentry?
- Space Race Meets Ground Reality for Tower REITs
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
Receive News & Ratings for Kyntra Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyntra Bio and related companies with MarketBeat.com's FREE daily email newsletter.
